Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of Fidrisertib (BLU-782) in Healthy Volunteers
NCT03858075Phase 1Completed
- Sponsor
- Blueprint Medicines
- Start
- Feb 2019
- Primary completion
- Sep 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of Fidrisertib in fibrodysplasia ossificans progressiva (FOP) (6 arms), sponsored by Blueprint Medicines. Primary endpoints: Incidence and severity of adverse events (AEs) through Day 8 with a single dose, Incidence and severity of adverse events (AEs) through Day 17 with multiple doses and 1 more. Started Feb 2019; status: completed.
02
Drugs
Fidrisertib
03
Conditions
fibrodysplasia ossificans progressiva (FOP)
Beyond the preview
Go deeper on NCT03858075.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03858075.